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Abstract 
South African medical schemes (health insurance or 
medical aid) companies offer insurance to the general 
public in the form of a multitude of different schemes. 
Each scheme has its own unique range of benefits, but 
certain exclusions apply across the board in respect of all 
schemes operated by a medical aid. In this research 
report, I investigate the rationale and necessity, as well 
as some of the ethical and legal implications of numerous 
notable exclusions. I further make relevant 
recommendations with respect to their application within 
the legal and ethical framework of the South Africa’s 
Consumer Protection Act, No. 68 of 2010. 
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Nomenclature  
 
“Medical schemes”, “health insurers” and “medical 
aids” in the South African context are terms used 
synonymously. 
 
The terms“patient”, “consumer” and “(scheme) 
member” are sometimes used synonymously. By means 
of a brief explanation, in the context of a medical 
consultation, the person consulting with a physician is 
termed a patient, in the context of the Consumer 
Protection Act, that same person is termed a “consumer”, 
and in respect of the relationship between that person 
and the medical scheme to which they belong, that same 
person will be referred to as a “member” of such scheme. 
 
“Normal health” shall meanthe level of health of the 
average South African resident; 
 
“Optimum health” shall meanpeak or near peak levels 
of health in an ideal circumstance; 
 
“restorative treatment” shall mean any treatment 
intended to restore the patient to the level of health that 
they had prior to the relevant disease / condition; 
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“professional sports people” shall in this context mean 
people that either earn their living from competing in 
sports, or compete at an elite level; 
 
 “Cost effective clinician” shall mean a doctor whose 
charges are viewed as reasonable in the context of the 
necessary treatment. 
 
“Open medical scheme”means a plan in respect of 
which membership is discretionary, and members join of 
their own free volition.  
 
“Closed scheme” means a scheme such as Bankmed, 
in respect of which employees do not have an option but 
to join such scheme. This is done for various reasons, 
whether ease of administration or the accumulation of 
group benefits according to critical mass. Closed 
schemes are not dealt with in this research report in 
significant depth because members do not have a choice 
to resign from the scheme and find a scheme which is 
more suitable; hence any discussion on the imperfections 
of such schemes would have little  effect, as the scheme 
management knows that there is no danger of loss of 
membership. 
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Chapter 1:South Africa and Medical Schemes: A Brief 
Overview 
 
1.1 South Africa and the medical schemes industry 
 
South Africa has a two-tier health system with a large 
private health sector, funded primarily from individual and 
employer insurance contributions, out-of-pocket payment, 
and government tax subsidies and a public health sector 
almost fully funded by public taxes. The health sector 
accounts for 8.7% of the country’s GDP – 3.5% of this 
expenditure is in the public sector (serving over 80% of 
the population) and the other 5.2% of expenditure is in 
the private sector (Mutyambizi, 2007:2). 
 
Private Mutual Health Insurers or Medical Schemes have 
existed in South Africa for over 100 years (Söderlund & 
Hansl 2000: 378). With the early economic boom during   
the 1800’s (primarily due to developments in the mining 
industry) some levels of private funding for health care in 
South Africa can be traced back to as early as 
1889(Pearmain, 2000:183). Concurrently, from the 1800’s 
to at least the advent of Medical Scheme regulations in 
1967, there was little emphasis placed on the public 
provision of health insurance.  This of course, was mainly 
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due to the Apartheid system then in place. For the 
majority of the population, health care provision during 
this time was largely managed by international, local, 
religious and other non-governmental institutions  who set 
up hospitals and clinics in the ‘homelands’ as well as 
other, mainly rural areas.  
 
With the advent of a more formal development of 
industry, medical schemes grew in keeping with Western 
trends of the time viz. ingenious marketing strategies of 
the medical health industry which included the 
promulgation of the idea that employers should provide 
some type of basic health coverage for employees. In 
South Africa, medical schemes developed and largely 
prospered. One reason for this was that they were largely 
unregulated by the government.  
 
In 1967, the promulgation of The Medical Schemes Act 
(Act 72 of 1967) set out to both recognise and regulate 
the medical schemes industry. As reported by Söderlund 
& Hansl (2000: 378) from 1969 until about the mid-1980’s 
the government became a major voice in the 
management of medical schemes. For example, at that 
time differential premiums based on poor-health risk were 
considered illegal (van den Heever, 1998: 282).  
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As was the general trend in most other countries,, the 
bulk of health care insurance then, as now, is provided by 
an employer for the purpose of employee benefit and as 
a buffer against possible legal claims against the 
employer in the case of a catastrophic event.  Such 
health insurance coverage is ‘designed’ as business or 
industry-specific, in what is referred to as a ‘closed 
fund’(Söderlund et al. 1999). In other words, the medical 
scheme is tailored to suit employee healthcare needs 
which are pre-determined by the particular medical 
scheme that the employer chooses. As Pearmain 
(2000:184) notes, “... in 1960 there were 169 schemes 
covering 1.5 million persons”. This proliferation of medical 
schemes, regulated to benefit the minority population was 
the general mode of operation until the mid 1960’s. 
 
In 1967, a Medical Schemes Act was passed in South 
Africa which was altered by numerous amendments.  
Despite these challenges the Act remained unaltered. 
(Söderlund & Hansl 2000: 378). Yet, in 1993 the most 
important amendment came about which would change 
the face of the industry, namely deregulation (Pearmain 
2000: 184). At this time, small-group and individual 
medical scheme coverage became available; known as 
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‘open funding’ (ibid). Practically, one of the consequences 
of this was that medical schemes now were allowed 
detailed and individual-specific risk rating e.g. 
assessment of previous claims, medical history as well as 
an individual’s current health status (Pearmain 2000: 
185). Other effects were that benefits for the elderly were 
diminished or their premiums were raised in accordance 
with risk profiling. Generally, the industry’s focus shifted 
as its structures and benefits were geared to attract the 
young and healthy.  
 
With deregulation, medical schemes essentially were 
facilitated to be run as highly profitable businesses. 
Medical scheme brokers, administrators, managed care 
organisations and boards of directors are examples of the 
groups which played a part of the network of affiliations 
which added bulk and political weight to the medical 
schemes industry. Overall, it was reasoned that the 
deregulation would lead to greater industry growth, 
benefit the business sector, and provide a larger taxation 
base which would benefit the country’s economic growth. 
 
As medical schemes became economically viable as 
businesses, this contributed to the capitalist system. The 
government backed off, to at least a considerable extent, 
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it’s hither-to control of the medical schemes industry 
allowing the ideas of e.g. for-profit as well as their 
perceptions of the rising costs of medicine to inform their 
actions (Söderlund & Hansl 2000: 379).     
 
In 1998, new legislation came into place with the Medical 
Schemes Act,No. 131 of 1998. This Act introduced further 
changes, including: a compulsory minimum benefits 
package, applicable to all schemes;a prohibition on 
discrimination on the basis of age, medical history and 
health status;requiring that contributions / premiums be 
determined only on the basis of income and / or number 
of dependants;a prohibition on medical schemes 
excluding applicants for membership, or their 
dependants, except under certain prescribed conditions; 
andregulating administrators and other contractors to 
medical schemes, for example brokers and managed 
care organisations (Pearmain, 2000: 185 - 187). 
 
Section 3 of the Medical Schemes Act, No. 131 of 1998, 
introduced for the first time the Council of Medical 
Schemes, whose function it is to: 
protect the interests of the beneficiaries at all 
times;control and co-ordinate the functioning of medical 
schemes in a manner that is complementary with the 
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national health policy;make recommendations to the 
Minister on criteria for the measurement of quality and 
outcomes of the relevant health services provided for by 
medical schemes, and such other services as the 
Council may from time to time 
determine;investigatecomplaints and settle disputes in 
relation to the affairs of medical schemes as provided 
for in this Act;collect and disseminate information about 
private health care;makerules, not inconsistent with the 
provisions of this Act for the purpose of the performance 
of its functions and the exercise of its powers;advise the 
Minister on any matter concerning medical schemes; 
andperform any other functions conferred on the Council 
by the Minister or by this Act.  (Medical Schemes Act, 
No 131, 1998)1 
The status quo within the Medical Aid industry is that 
different schemes provide several different benefit 
options at differing contribution levels. All schemes are, 
however, required to provide unlimited access (without 
                                                 
1(1) A medical scheme shall apply to the Registrar for the approval of 
any benefit option if such a medical scheme provides members with 
more than one benefit option. 
 
(2) The Registrar shall not approve any benefit option under this 
section unless the Council is satisfied that such benefit option— 
a) includes the prescribed benefits; b) shall be self-supporting in 
terms of membership and financial performance; c)is financially 
sound; and d) will not jeopardize the financial soundness of any 
existing benefit option within the medical scheme “(Medical Schemes 
Act, Act 131, 1998 Section 33). 
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any co-payment) to a defined set of statutory minimum 
benefits called Prescribed Minimum Benefits (PMB). This 
is designed in a way to ensure that medical schemes 
provide substantial coverage to their members to guard 
them against catastrophic costs. This refers to the 
provision of substantial cover in respect of conditions 
frequently seen in the general populous. These 
Prescribed Minimum Benefits (PMBs) were reintroduced 
by legislation in 2000. The PMBs cover all non-elective 
hospitalisations and outpatient care for any emergency 
condition, a specified list of 270 medical conditions 
(defined by the Council for Medical Schemes as 
“Diagnosis Treatment Pairs”) and 26 chronic conditions2. 
 
The divisions of who has health insurance and who does 
not, and the reasons behind this wide division is a topic 
which continues to be debated by numerous and diverse 
groups of people such as economists, politicians, health 
policy experts as well as ethicists (Hoogeveen & Özler 
2005; Wollard 2002;  May 1998; Benatar 1991: 33).  The 
greatest problems in this regard, appear to be those 
which concern justice – the attempts to find ways in which 
goods / services can be more equally distributed.  
                                                 
2
 Detailed explanations of emergency conditions, the 270 Diagnosis 
Treatment Pairs and the 26 Chronic conditions can be found on the 
internet website for the Council for Medical Schemes, namely 
(http://www.medicalschemes.com), which is periodically updated. 
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While that area of research is fascinating, in this research 
report I will focus on some of the medical schemes in the 
context of their relationship to their members and the 
possible ramifications of the Consumer Protection Act in 
South Africa. To the best of my knowledge, this is an area 
which has not been researched.  
 
1.2 The need for medical insurance 
Medical Aid, or Medical Insurance, for many South 
Africans has become a non-negotiable necessity. This is 
due mainly to the fact that it is felt, or is actually a truism,  
that the level of care and / or the facilities offered at state 
clinics and hospitals are largely sub-standard (Cullinan, 
2006:3). Yet there is a problem because at the same 
time, the costs of private healthcare, being the medical 
schemes, doctor’s consultations, clinics and hospitals, 
have progressivelybecomemore and more expensive 
(Schreyögg, 2004: 689).  
 
Private healthcare practice in post-modern South Africa 
could not survive without medical schemesor other forms 
of medical insurance in whatever guise. While submission 
of medical aid claims affords doctors a reasonable 
guarantee of payment, it simultaneously greatly reduces 
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the medical profession’s bargaining power in fee-
negotiations, as it affords the medical insurance 
companies inordinate leverage (Le Roux, 2004). 
 
In the interests of ensuring that one has access to first-
world medical facilities, and in exchange for a monthly 
premium, medical schemes offer varying degrees of 
funding for private hospital and medical care. The 
concept seems quite noble – bridging the gap between 
the average citizen and world-class medical services, 
which would ordinarily fall outside of the ambit of one’s 
disposable income. If this is the case, then what is the 
problem?   
 
1.3 Overview: Concepts of Justice and widening 
divisions in income and healthcare in South Africa     
 
As previously mentioned, the divisions of who has health 
insurance and who does not, and the reasons behind this 
wide division is a topic which continues to be debated by 
numerous and diverse groups of people such as 
economists, politicians, health policy experts as well as 
ethicists (Hoogeveen, & Özler 2005; Wollard 2002;  May 
1998; Benatar 1991: 33).  The greatest ethical issues in 
this regard appear to be those which concern justice – 
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the attempts to find ways in which goods / services can 
be more equally distributed amongst a society.  
 
Three models of justice are particularly evident in the 
context of healthcare. Each of them generally involves 
what a given society considers as a fair distribution of 
resources for its population. They include the tenets of 
fairness, the ideas of comparative justice and distributive 
justice (Asch & Ubel, 1997: 1669).  
 
John Rawls (1971: 1-18) in his work A Theory of Justice 
considers justice as absolute equality and fairness. For 
example, when we consider that South African medical 
schemes have in the past considered one’s race and age 
(or other distinguishing factors) as a reason to increase 
their premiums then we note that this does not conform to 
Rawls’s notion of justice-as-fairness.  
 
Comparative justice on the other hand, includes an 
assessment of the relative meaning people have in 
receiving a healthcare resource. For example, David 
Hume was concerned with comparative justice including 
the recognition of the limited nature of resources. In his 
model of comparative justice, he strikes a compromise 
between Rawls’ justice as fairness (in which the ideal is 
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the provision of treatment based on only need) and 
acknowledgment of the limited pool of resources from 
which to provide the treatment. In this view, a needs 
assessment is carried out and treatment is given 
accordingly (Berglund, 1977: 43-52).  
 
Distributive justice has as its focus the allocation of 
resources based not just on need, but on what each 
given society considers as an appropriate distribution of 
benefits and burdens. In other words, it represents a 
social consensus on the problems of allocation of rights, 
duties, benefits and burdens amongst society’s members 
(Dickens, 1994: 315). Distributive justice is particularly 
important in the developing world context. In South Africa, 
for example, the gap between the ‘haves’ and the ’have 
nots’ is widening. Within the general category of poverty, 
extreme poverty is increasing. Even within the black 
African population, the inequality brought about by 
extreme poverty has increased during the last decade 
(May, 1998).  
 
South Africa has, in practice, a two-tiered healthcare 
system. Concerning health insurance, it is funded for the 
most part by the private sector funds such as employer, 
group and individual contributions. The public sector, on 
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the other hand, relies principally on government taxation 
for its survival (Benatar 1991).  
 
According to Mutyambizi (2007: 2-4) the health sector 
accounts for 8.7% of the country’s GDP – 3.5% of this 
expenditure is in the public sector (serving over 80% of 
the population) and the other 5.2% of expenditure is in 
the private sector (serving less than 20% of the 
population). 
 
The topic of justice in healthcare delivery for all 
individuals in South Africa is vitally important. Perhaps 
this is why the current government is working towards a 
National Health Insurance for clearly in our current South 
African healthcare situation, little justice, considered as 
fairness, comparative or distributive is evidenced. As 
important as this topic is, it is not the focus of my 
research report.   
 
1.4 Justice as the sub-text in the relationship 
between medical scheme and member  
 
Justice, in whatever situation conceived is an infallible 
human concept. Issues of justice should not be confined 
to only certain times, events and places. Rather it should 
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be malleable. In this research report I will look at justice 
broadly through a different frame.  
 
 
I suggest that it is in the artistry or maleficence, 
dependant from which perspective one examines the 
relationship between medical scheme and member, of 
the scheme’s details ensconced in the membership 
contracts and in the terms / conditions of the medical 
schemes that one may question the rationale behind the 
nature of certain exclusions.  
 
In the following chapters I will consider the relationship 
between medical schemes and their members. Then I will  
place particular emphasis on the types of medical and 
other conditions commonly deemed as “exclusions” by 
the medical schemes industry, questioning their 
reasoning in the context of justice as  equity meaning 
“that all individuals be provided “equal” opportunities to 
actualise their health potential regardless of whether the 
differences in groups are narrowed or not” ( Chang 2002: 
489).    
 
We can all agree that being in the business of healthcare 
involves contracts / quasi-contracts, and the exchange of 
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money for services (Fryback & Lawrence, 1997: 277-
279). We can also agree that when people disagree with 
a model in operation that they may choose to object. 
Patients and consumers can also voice frustration with 
how some resources are used (Zeithaml, Berry & 
Parasuraman, 1996: 32), how some exemptions are 
articulated and others not (Belèn del Rio-Lanza, et al. 
2009: 779)  and about how long it seems to take for their 
healthcare needs to be met or their grievances heard 
(Hall, 2008). These factors all involve justice in some way 
or another through patient or consumer perceptions of 
e.g. service, emotions, thoughts, desires and needs. With 
this in mind I will hold medical schemes to the South 
African Consumer Protection Act. In this way I will try to 
show how justice and consumer protection may work in 
tandem.  
 
To the best of my knowledge, this is an area which has 
not been previously researched.  
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Chapter 2: Species of Medical Schemes 
 
The United Nations Organization for Economic Co-
operation and Development (OECD) presents a 
taxonomy that distinguishes between public and private 
health insurance on the basis of funding source 
(Normand &Busse, 2000:64). In this view, public funding 
of medical insurance derives from house-hold or 
employer income which is then channelled through to the 
state by means of general or social insurance taxes. In 
private health insurance, money is paid directly to the 
risk-pooling entity- the medical scheme. South African 
medical schemes, with the exception of those closed 
schemes whose membership is limited to civil servants, 
are generally privately funded. 
 
Private medical insurance is often colloquially regarded 
as a voluntary for profit commercial coverage as opposed 
to “public managed insurance” which is both publically 
managed and financed. It is important to note that there 
are quite a variety of medical insurance types globally 
and that the distinctions between public and private are 
increasingly blurred.  
 
The public generally assumes that membership of private 
medical schemes is generally voluntary, yet in some 
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countries they are not. For example in Uruguay and 
Switzerland   private health coverage is mandatory; in 
Mexico, it is voluntary (Sekhri&Savedoff, 2005: 128). In 
addition, as Sekhri&Savedoff note, there are global 
variants in contributions to medical schemes, as although 
they tend to be rated by risk or community-risk, this is not 
always the case. Perhaps one of the most striking myths 
surrounding private medical schemes is that they are 
privately owned. Australia, Ireland and India are 
examples provided which point out that the largest private 
health insurance companies are publically owned (Ibid).  
 
So we can see that there are some common 
misunderstandings an ordinary person may have about 
private health insurance companies because in their 
types, management and status, they are not globally 
categorical.  Importantly, there is variability in the role (or 
roles) that private health insurance companies may play 
in a country’s health financing system. In some countries, 
enrolment of its citizens in a health insurance company 
may be voluntary, the contributions are community –
rated, yet it may be managed as a public company. In 
others, a publicly funded health insurance company may 
consist in mandatory enrolment, be income-based, and 
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managed as a non-profit entity. So to typify all health 
insurance companies as the same is a misconception.     
 
Debate has developed over the need to shield patients 
from various undesirable features of the perceived 
paternalistic approach of“managed care”. What is meant 
by managed care is the scheme’s micro-management 
and involvement in areas such as disease management, 
utilization review, physician profiling and the use of broad 
spectrum guidelines and protocols (Holčik, 2001:1). 
 
This backlash is now being vociferously expressed by the 
movement known as “consumer directed health care”, 
which seeks to re-establish the economic dominance of 
the doctor-patient relationship, free from interference by 
health insurers (Hall, 2008:586). 
 
Consumer-driven health plans have incorporated health 
benefit options available to employees in many large 
companies (Parente et al.,2004: 1190-1191). In the 
interests of improved staff health and hence greater 
productivity, many South African employers prefer their 
employees become members of such medical schemes.  
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A consumer-driven health plan purports to involve the 
consumer in their own healthcare decision-making. There 
are different ways of formulating this, but it is interesting 
to note the use of industrial psychology in some of the 
methods. For example, some medical schemes employ a 
technique that provides the member with his or her own 
‘healthspending’ or ‘health savings account’. From this 
account, the member chooses and has the opportunity to 
purchase his or her healthcare service/s. Usually there is 
a form of a major medical coverage clearly indicated as a 
benefit in this scheme design; a ‘wrap-around’ giving the 
member security (Ibid). Should the member spend all of 
his or her savings/spending account in a given year, then 
the member is compelled to use his or her personal funds 
for healthcare needs until the deductible obligation is met 
(ibid). 
 
While this particular design varies from scheme to 
scheme (it can be planned to cover expenditures in 
excess of the deductible in part or wholly) emphasis is 
placed on the choices available to a member. Some 
medical schemes, in the name of informed decision-
making, provide their members with information 
concerning their healthcare providers, which may include 
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their educational background, experience , fees for 
service and what are called their ‘quality ratings’(ibid).      
 
Information regarding one’s medical scheme is usually 
available on the internet in order to ensure easy access 
(Christianson, Parente, and Taylor, 2002: 49), but South 
African Medical schemes, to be fair, cannot publicise 
specific information about health care providers, including 
physician education and experience, prices, and ‘quality 
ratings’. This is because such acts would contravene 
local anti-competitive legislation.  
 
Certainly, the idea of a ‘quality rating’ would cause at 
least a flurry of feathers in the healthcare profession 
community as an assessment of the quality of the doctor-
patient / healthcare professional –patient relationship is 
often subjective and extremely difficult to quantify or 
qualify on a large scale. However, from a legal 
perspective, the publication of e.g. a healthcare 
professional’s poor ‘quality rating’ could be considered 
defamatory if publicized. 
 
In this very brief synopsis, I have tried to illustrate the 
context within which the South African medical aid sector 
relates to the subject matter of this research report.  
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Chapter 3:Phraseology of Medical Aid 
Contracts 
 
In terms of section 2.4 of the Health Professions Council 
of South Africa National Patients’ Rights Charter,  
“A member of a health insurance or medical aid 
scheme is entitled to information about that 
health insurance or medical aid scheme and to 
challenge, where necessary, the decision of such 
health insurance or medical aid scheme relating 
to the member “(Health Professions Council of 
South Africa (i), 2008) 
 
The key information, as far as many consumers / 
members are concerned, is what their medical scheme 
will not pay for. In this regard, it is necessary to examine 
specific exclusions as applicable in the South African 
Medical Aid industry. 
 
What follows is a brief examination and discussion of the 
exclusions that are applicable to five of the largest 
medical schemes in the country.3 
                                                 
3Membership figures for the below-mentioned medical schemes as at 
January 2011 are: 
Discovery: 2 500 000; 
Fedhealth: 75 000; 
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3.1 Specified Exclusions 
 
While the position of a person who is interested in the 
types of exclusions may differ according to his or her 
particular healthcare interests, I have chosen the 
following simply to demonstrate some of the different 
types of exclusions.  (The table below is intended to 
serve as illustrating most if not all exclusions that could 
affect a consumer on a day to day basis, and as such, the 
exclusions of the five medical schemes cited were 
deemed sufficient for the purpose this research report.) 
 
Table 1: Comparison of exclusions between Discovery, Spectramed, Fedhealth, 
Oxygen and Bankmed 
No. Exclusion: Discovery Spectramed Fedhealth Oxygen Bankmed 
1 
General Elective Cosmetic Procedures 
√ 
 
 
 
√ 
 
 
 
√ 
(unless directly 
caused by or 
related to 
illness, 
accident or 
disease) 
√ 
 
 
 
unless 
medically  
necessary 
and pre-
authorised 
 
2 
Breast Reductions (inclusive of 
healthcare services related thereto) √ √ 
unless 
medically  
necessary and 
pre-authorised √   
3 
Breast Enlargements (inclusive of 
healthcare services related thereto) √   
unless 
medically  
necessary and 
pre-authorised     
4 Breast Reconstruction   cosmetic 
unless 
mastectomy 
following 
cancer and 
pre-authorised     
5 Gynaecomastia √   √ √   
6 Rhinoplasties     
for cosmetic  
purposes     
7 
Abdominoplasties and the repair of 
divarication of the  
abdominal muscles     √     
                                                                                                        
Oxygen: 91 490; 
Spectramed: 83 000; and 
Bankmed: 100 000. 
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8 
Obesity (inclusive of healthcare 
services related thereto) 
 
√ 
 
√ 
(including 
surgery in 
respect 
thereof) 
√ 
 
√ 
 
√ 
 
9 
Frail care (inclusive of healthcare 
services related thereto) √ √     √ 
10 
Infertitlity (inclusive of healthcare 
services related thereto): 
Assisted Reproductive Technology 
(ART): 
In-vitro fertilization (IVF): 
Gamete Intrafallopian tube transfer 
(GIFT): 
Zygote Intrafallopian tube transfer 
(ZIFT):  
Intracytoplasmic sperm injection (ICSI): 
√ 
 
 
 
 
√ 
 
 
 
 
√ 
√ 
√ 
 
√ 
 
√ 
√ 
 
 
 
 
√ 
 
 
 
 
11 
Vasovasostomy (reversal of 
vasectomy)     √     
12 
Salpingostomy for reversal of tubal 
ligation     √     
13 
Wilfully self-inflicted illness or injury 
(inclusive of healthcare  
services related thereto) √ √ 
unless 
covered 
 by PMB's 
only by  
beneficiary  √ 
14 Alcohol, drug or solvent abuse √   √     
15 
Wilful and material violation of the law 
or during a period of imprisonment 
(inclusive of healthcare services related 
thereto) √ √       
16 
Wilful participation in war, terrorist 
activity, riot, civil commotion rebellion or 
uprising (inclusive of healthcare 
services related thereto) √ √ 
unless 
covered 
 by PMB's   
irrespective  
whether 
wilful or not 
17 
Experimental, unproven or unregistered 
treatments or practices √ √       
18 Search and rescue √         
19 
Side-effects or complications of 
excluded treatments (to the extent that 
same are not provided for in the list of 
Prescribed Minimum Benefits   √       
20 
Failure to follow the advice of a medical 
or dental practitioner 
 or to undergo health services/treatment 
as recommended by a medical or 
dental practitioner   √ 
only if such  
failure is 
deliberate √   
21 
Health care services relating to injuries 
sustained during participation  in 
professional sport, speed contests and 
speed trials   √       
22 
Health care services obtained out of the 
borders of South Africa   √   
except for  
Lesotho and 
Swaziland   
23 CT Angiogram of coronary vessels   √       
24 
Any benefit not specifically stated in the 
scheme rules   √ √     
25 
Treatment in respect of which a 3rd 
party may be liable √ √     √ 
26 Holidays for recuperative purposes     √ √ √ 
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27 
Erectile dysfunction 
 
 
 
 
    
√ 
(including 
surgical 
procedures in 
respect 
thereof) √ √ 
28 
The purchase of medicines prescribed 
by a person who is not  
legally entitled to do so     √ √ √ 
29 
Costs for services rendered by 
(medical) personnel not registered with 
a professional body constituted in terms 
of any law      √ √ √ 
30 
Services that do not relate to any 
sickness condition, including  
but not limited to examinations for 
insurance, employment, visas,  
pilot and driving licences or school 
readiness tests       √ √ 
31 Sleep Therapy     √ √ √ 
32 
Any drug or medicine not registered by 
the Medicines Control  
Council or similar authority or 
medicines not registered for that 
specific condition     
unless Section 
21  
approval 
obtained & 
pre-authorised 
by  relevant 
managed 
healthcare 
programme √   
33 Orthognathic (Jaw Bone) Surgery   √   √   
34 
Any specialised drugs that have not 
convincingly demonstrated a survival 
advantage of more than 3 (three) 
months in metastatic  
solid organ malignant tumours     √ √   
35 Cochlear implants     √ √   
36 
Contraceptives (oral or otherwise), 
IUCD's, parenteral and foams 
 
    
√  
(including 
when used for 
skin 
conditions) 
√ 
  
37 
Anabolic Steroids and 
Immunostimmulants     √     
38 
Health care services that, in the opinion 
of the medical or dental 
 adviser, are not appropriate and 
necessary for the symptoms, diagnosis 
or treatment of the medical condition at 
an affordable level of service and cost     √ √ √ 
39 
Alternative Health Therapists: 
Herbalists: 
Iridology: 
Reflexology: 
Therapeutic Massage: 
Ayurvedics:     
√ 
√ 
√ 
√ 
√     
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40 
Blood Products: 
Erythropoietin: 
 
 
Hemopure (haemoglobin polymer 
synthesised from bovine haemoglobin)     
 
unless pre-
authorised 
 
 
√     
41 
Maternity: 
3D and 4D scans 
 
 
 
 
2D scans 
 
 
 
 
ante-natal classes/exercises 
 
    
 
√ 
 
No more than 
two, unless 
motivated for 
an appropriate 
medical 
condition 
 
√ 
 
    
42 
Cancer Treatments: 
trastuzumab for the treatment of HER2-
positive early breast cancer  
 
 
 
 
 
 
 
 
 
any specialised drugs that have not 
convincingly demonstrated a survival 
advantage of more than 3 (three) 
months in metastatic solid organ 
malignant tumours, for example 
sorafenib for hepatocellular carcinoma, 
bevacizumab for colorectal and 
metastatic breast cancer 
 
Imatinib in the treatment of chronic 
myeloid leukaemia and  
gastrointestinal stromal tumours     
unless forms 
part of public 
sector protocol 
and is 
authorised by 
relevant 
managed 
healthcare 
programme (if 
exceeds 9 
week regimen) 
 
unless forms 
part of public 
sector protocol 
and is 
authorised by 
relevant 
managed 
healthcare 
programme 
 
 
 
√ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
√ 
 
   
43 
New indications for existing medicines 
that have not been reviewed by the 
relevant managed healthcare 
programme     √     
44 
Smoking cessation and anti-smoking 
preparations     √     
45 
All benefits for clinical trials unless pre-
authorised by the relevant  
managed healthcare programme     √     
46 Growth Hormone     
Unless  
pre-authorised     
47 Organ Donation     
excluded 
unless  
recipient is 
member / 
dependant of 
member of the 
scheme     
 - 37 -
48 
Haemopoeitic stem cell (bone marrow) 
donations     
excluded 
unless  
recipient is 
member / 
dependant of 
member of the 
scheme     
49 MRI Scans     
if ordered by 
General  
Practitioner, 
unless no 
reasonable 
access to 
specialist     
50 
Uvulo palatal pharyngoplasty (UPPP 
and LAUP for snoring)     √     
51 Autopsies     √     
52 
Costs for medical treatment as a result 
of exposure to Nuclear or  
Radioactive waste     √     
53 
Cryo-storage of foetal stem cells and 
sperm     √     
54 Telephonic consultations     √   √ 
55 
Hazardous Activities: 
Military / Para-military service: 
Advanced rope climbing: 
Rope assisted climbing: 
Rock Climbing: 
Power boat racing: 
Scuba Diving > 40m depth         
√ 
√ 
√ 
√ 
√ 
√ 
56 Travelling Expenses     √ √ √ 
 
Notes 
 
i. The aforementioned exclusions were sourced from the 
internet websites of the relevant medical schemes during 
August 2010, and as at such date, were current and up to 
date (Bankmed, 2010; Discovery Health, 2010; Fedhealth 
Medical Scheme, 2009; Oxygen Medical Scheme, 2010; 
Spectramed Medical Scheme, 2010). 
 
ii. The above exclusions do not take into account provisions 
in relation to Dentistry and Optometry benefits, but relate 
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to medical conditions and other factors that are frequently 
seen in practice. 
 
iii. Conditions and / exclusions such as "Blue Door" which 
bare a statistically fractional significance, have been 
excluded from the above list. 
 
3.2 Discussion: 
 
Interestingly, with respect to its above mentioned 
exclusions, Fedhealth defines “medically necessary” as 
services or supplies that meet all of the following 
requirements: 
 
 The desired treatment or procedure must be 
required to restore normal function of an affected 
limb, organ or system; 
 
 No alternative exists that has a better outcome, is 
more cost-effective or has a lower risk; 
 
 They are accepted by the relevant service provider 
as optimal and necessary for the specific condition 
and at an appropriate level to render safe and 
adequate care; 
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 They are not rendered or provided for the 
convenience of the relevant beneficiary or service 
provider; and 
 
 Outcomes studies are available and acceptable to 
the scheme in respect of such services or supplies. 
 
It is submitted that the above constitutes an exceptionally 
narrow window of what is capable of being deemed 
“medically necessary”. It does not allow for new and 
innovative treatments or for multi-faceted medical 
problem solving. It seems to constitute a term that is both 
unconscionable and unjustly restrictive. 
 
For example, the member, in a situation of a treatment or 
procedure deemed “medically necessary” is assured that 
“outcome studies are available and acceptable to the 
scheme in respect of such services or supplies”. While 
members are assured that outcome studies are available 
and acceptable, it may be argued that in the interests of 
fairness, these outcome studies should be available and 
acceptable to members as well. This is because 1) the 
average scheme member has no knowledge of the 
empirical studies which ground the medical scheme 
decisions, particularly whether they represent current 
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knowledge, and 2) in a situation of a medically necessary 
treatment or procedure, it is unlikely that the scheme 
member will even recall that they may have a chance to 
question what the medical scheme has deemed 
appropriate action.  
 
 As mentioned earlier, the business of healthcare involves 
an exchange of money for services(Fryback & Lawrence, 
1997: 277-279). From the perspective of a medical 
scheme, it is in their interest to provide benefits at 
minimum cost to themselves. It is of utmost importance to 
consider that equity means that all individuals be 
provided with equal opportunities to realise their health 
potential (Caplan, et al. 1999: 854-855). Without 
knowledge concerning the facts behind the scheme’s 
decision of what they consider ‘acceptable’ the member 
remains ignorant. In this example, we can see that the 
notion of equity is sorely lacking.     
 
 Furthermore, why should one merely be entitled to be 
restored to normal function / health as opposed to 
optimum function / health? This question is particularly 
pertinent for sportsmen and / or persons who lead a 
largely active lifestyle. Considering how low the generally 
accepted standard of normal functioning / health is, 
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surely, if relevant and appropriate, members should be 
entitled to restorative treatment aimed at the maximum 
possible benefit? In this way, not only will the medical 
schemes facilitate the evolution of proactive medicine, but 
also provide sufficient value to the Principalist pillars of 
patient (scheme member) autonomy and beneficence. It 
is pertinent to note at this point that autonomy (or the 
right to self-determination) is a fundamental ethical 
principle underlying informed consent (Dhai&McQuoid-
Mason, 2011), which is itself a formality required for any 
medical intervention and the information given must 
assist the patient in making the best possible decision 
(Ibid). It is submitted that the best possible decision in 
such circumstances would be the restoration of optimum 
functioning and / or health. 
 
The implicit corollary of this, however, is that Fedhealth 
gives the impression that “only the best proven drugs, 
treatments or procedures shall suffice”. It may well be 
difficult for such medical schemes to insist on generic 
substitution of patented drugs in the face of a member 
objection. This aspect will be discussed further under the 
heading of “Original versus Generic Drugs”. 
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3.3Problematic Express / Implicit Provisions in 
respect of the above Exclusions: 
 
Inasmuch as the above exclusions arephrased with 
varying degrees of comprehensiveness and elaboration, 
certain exclusions, whether express or implied, require 
further examination: 
 
3.3.1 Health care services necessitated as a result of 
side-effects caused by the use of prescribed (and 
approved) drugs: 
 
Although none of the schemes cited above expressly 
exclude health care services necessitated as a result of 
side-effects caused by the use of prescribed (and 
approved) drugs, numerous schemes, including several 
cited above, have refused to pay for the treatment of the 
side-effects / consequences of certain approved 
treatments. The “justification” for such repudiation is that 
the corrective procedure falls within the vague ambit of 
one of the cited exclusions, and hence cannot be paid for 
with scheme funds. 
 
In truth, if the drugs and / or treatment approved by the 
medical scheme were the direct cause of the condition 
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from which the member now suffers, the scheme is 
ethically bound, from the perspective of both justice and 
non-maleficence, to pay for any treatment necessary to 
correct such conditions, regardless as to whether one of 
the scheme’s exclusions is phrased broadly enough so as 
to be capable of being interpreted as covering the 
condition in question. Not paying for corrective treatment 
would be tantamount to paying for knee or hip 
replacement surgery but refusing to pay for requisite 
physiotherapy thereafter. Indeed, the physiotherapy was 
only necessitated on account of the orthopaedic surgery, 
but it was a known consequence thereof, without which, 
the surgery would lose much of its intended benefit. 
 
On the basis that none of the aforementioned medical 
aids exclude health care services necessitated as a result 
of side-effects caused by the use of prescribed (and 
approved) drugs, it is submitted that any requisite 
corrective treatment should be interpreted as being an 
implied inclusive benefit of the scheme. 
 
3.3.2Breast Reconstruction for Females due to 
Mastectomy: 
In these times, the psycho-social healthcare model which 
includes a holistic view on healthcare is promulgated in 
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medical school teaching and practice. In this way of 
thinking, the patient’s body is part of the medical 
dynamic, yet it is realised that a patient is not just a body.  
 
Rather he or she is a whole being living in a web of social 
relationships. By social relationships, we mean that he or 
she lives in a particular time and place and inevitably his 
or her culture, traditions, media influences, religion, 
education, etc. are part of his or her social identify.  
 
While breast cancer is predominately found in females, it 
may also occur in males. (Fentiman, 
Fourquet&Hortobagyi, 2006: 595) Applicable to both 
sexes, there are some surgical procedures which are 
practiced for removal of carcinoma of the breast such as 
a ‘lumpectomy’ where, because of the type, location, and 
size of the tumour, it is feasible.  
 
A mastectomy,4which is the surgical procedure to remove 
a breast and related lymph glands remains the most 
common surgical procedure for breast cancer treatment  
(Martin,2007: 432). The removal of any malignant tumour 
in one’s body is, by its very nature, not an elective 
                                                 
4Removal of both breasts is commonly called a total mastectomy. 
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procedure.Such procedures are performed to save or at 
least prolong the patient’s life.  
 
While no literature is available concerning the 
psychological responses of males post breast cancer 
surgery, it is quite different with women. It is part of the 
history of humans as evidenced through literature and the 
arts that the female breasts are directly linked to ideas-be 
they right or wrong-about fertility, motherhood, femininity, 
and ‘womanhood’. It would follow that in cases of breast 
cancer in females a good outcome should aim to combine 
both the physical and mental well-being of the patient.  
(Passik, Newman, Brennan & Holland, 1993: 226; 
Stevens et al. 1984: 619). 
 
Frequently, women who have undergone mastectomies 
develop post-operative depression, diminished self-
esteem, and impaired sexual, social and occupational 
functioning, as well as other psychiatric conditions as a 
direct result of their apparent loss of “womanhood” (Al-
Ghaza, Fallowfield& Blamey, 2000: 1938; Stevens et al, 
1984: 619). 
 
Due to these factors, and admittedly there will be degrees 
of individual variation of psychological response, there is 
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good reason to argue that, for those women who believe 
they need breastreconstructive surgery, they should 
receive it. This would support the contemporary emphasis 
on viewing the patient as an entire person. It is submitted 
that regardless whether a particular medical aid 
specifically excludes cosmetic surgery or breast 
augmentation surgery (which term is periodically and 
incorrectly used synonymously with “breast reconstructive 
surgery”), a member’s claim for breast reconstructive 
surgery as a result of a mastectomy for a breast 
malignancy should not be repudiated. 
 
3.3.3Breast Augmentation / Enlargement – (medical 
grounds): 
Although not as dramatic as breast reconstructive surgery 
necessitated by a mastectomy, sound psychiatric / 
medical reasoning for breast augmentation (enlargement) 
should be considered for coverage on a case-by-case 
basis by the medical schemes. Justifiable reasons might 
include, for example cases in which there is abnormal 
breast development or in cases in which clinical 
depression  (in various guises) occurs because the 
woman considers that she is not “feminine” enough 
(Schlebusch& Levin 1983: 481).This is not to suggest that 
all women with “small” breasts should automatically 
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qualify for breast enlargement surgery, but rather that if 
the patient presents with a genuine psychiatric or 
borderline psychiatric condition on account of her breast 
size, it would only be fair and just that her case be 
considered on its individual merit. 
 
Every member is an individual with their own unique set 
of personal and medical circumstances. Hence, five 
members may require the same surgery for five different 
reasons. For the scheme to state that they shall not pay 
for the surgery because it falls under the category of 
cosmetic treatment would be to disregard theprinciples of 
justice and fairness, and would necessarily imply that all 
of the aforesaid five members presented with the same 
medical requirements, which would be a gross 
misinterpretation of the facts. 
 
Indeed, inasmuch as medical ethics obliges doctors to 
treat their patients as individuals, why should medical 
aids be permitted impose blanket bans on certain 
procedures / treatments, irrespective of the rationale 
therefore? 
 
Once again, from an economic perspective, should the 
patient’s psychological morbidity become sufficiently 
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significant, the scheme may well find that the cost of 
psychological / psychiatric treatment outweighs the cost 
of the desired surgery. 
 
3.3.4Breast Reduction (Mammoplasty) – medical 
grounds: 
 
Breast reduction surgery can be motivated from a 
medical perspectivebecause of the neck, shoulder and 
back pain that may be caused by the excess weight 
increasing the strain on the musculature of the affected 
areas. In such cases, the muscles and skeletal system 
are incapable of supporting the increasing weight of the 
breasts (Klassen et al.,1996: 454). This pain can, in 
certain circumstances, be significant. Furthermore, the 
woman in question is likely to feel “ungainly” and her self-
esteem (and general psychiatric health) isadversely 
affected by breasts that are out of proportion to the rest of 
her body.  
 
A British study in 1996 showed that breast reduction 
surgery produced substantial positive changes in 
patients’ physical, social and psychological function. The 
proportion of cases of possible psychiatric morbidity fell 
from 41% before surgery to 11% six months after 
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treatment. The study provides empirical evidence that 
supports the inclusion of breast reduction surgery in NHS 
(National Health Insurance) contracts (Ibid). 
 
From an economic perspective, regardless of whether 
one refers to breast reconstruction, augmentation or 
reduction surgeries, if a woman is prescribed anti-
depressant medication and is required to consistently 
consult with a psychiatrist, the cost of such medication 
and treatment is likely to significantly outweigh the cost of 
the so-called “cosmetic” procedure. Consequently, 
permitting such proceduresmakes not only fiscal but 
holistic healthcare sense.5 
 
3.3.5Infertility 
 
Infertility treatments such as In-vitro Fertilisation (IVF), 
Assisted Reproductive Technology (ART),  
GameteIntrafallopian tube transfer (GIFT), Zygote 
Intrafallopian tube transfer (ZIFT) and Intracytoplasmic 
                                                 
5It is only fair at this juncture to acknowledge that 
Fedhealth and Bankmed do in fact make allowances for 
cosmetic procedures necessitated by medical conditions. 
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sperm injection (ICSI) are expensive (Phillips et al., 2000: 
95 - 106).  
 
One can understand, if only from a financial perspective, 
the initiative of the medical aids to exclude such 
treatments from their members’ benefits. Thatsaid, all of 
the above treatments, amongst others, have been shown 
to increase the likelihood of a full-term pregnancy and 
subsequent live birth when administered under medically 
appropriate conditions. The problem is that it is very 
difficult to determine which procedure is in fact “medically 
appropriate” for an individual patient.  
 
Section 12(2) of the Constitution specifically enshrines 
the right of every person to bodily and psychological 
integrity, including the right to make decisions about 
reproduction (Constitution of the Republic of South Africa, 
Act 108 of 1996).  
 
The decision whether or not to fund treatment of infertility 
often centres around resource allocation, the argument 
being that either that the (expensive) infertility treatment 
is either not medically necessary or is an elective 
procedure that the medical aid is not obliged to cover, 
and that if a given scheme were to cover such treatment 
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it would unnecessarily deplete the resources needed to 
treat other members in more dire circumstances. 
However the principle of justice is a very important factor 
in resource allocation decisions. Using this principle, a 
more social approach to the distribution of resources is 
employed where the needs of others and not just the 
individual patient are taken into consideration (World 
Medical Association Declaration on the Rights of the 
Patient, 2005).The justice principle requires that where 
choices have to be made between patients for particular 
treatments, decisions must be based on sound medical 
criteria without discrimination – all patients to fair 
selection procedures.(Dhai&McQuoid-Mason, 2011). 
 
From the perspectives of patient autonomy and justice, if 
a member is paying for medical insurance to cover the 
costs of unforeseen medical circumstances as and when 
they may arise, and such member has a constitutionally 
entrenched right to make all relevant decisions regarding 
their reproduction, including which available technological 
innovations to utilise, then on what basis (legal, ethical or 
otherwise) could a medical scheme exclude such 
treatment from its payment protocol? It is submitted that 
in acknowledging their members’ Constitutional rights, a 
medical scheme should at least make a meaningful 
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financial contribution towards any medically necessary 
treatment of infertility. 
 
3.3.6Health care services in respect of injuries from 
professional sport: 
 
When we consider the ideals of fairness and justice in the 
context of sports activities we must then also consider the 
question of why professional sport is distinguished from 
amateur sport. One of the many benefits to playing 
professional sport is that medical care is readily available, 
and that referees and coaches are becoming more 
educated regarding the prevalence and nature of sports 
injuries as opposed to amateur sport. It could thus be 
argued that from a medical standpoint, one is more likely 
to be injured in an amateur sportthan its professional 
equivalent. 
 
A possible solution to this quandary is to examine certain 
high-risk sports, whether amateur or professional, on a 
case by case basis. 
 
3.3.7Health care services in respect of pre-
determined “Hazardous Activities”: 
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What seems to create difficulties with a provision such as 
this is who determines which activities are deemed to be 
sufficiently hazardous. Bankmed defines, amongst 
others, military / para-military service, advanced rope 
climbing, rope assisted climbing, rock climbing, 
powerboat racing and scuba diving at depths greater than 
40 meters as “hazardous”.  
 
If one is to be critical, then where does one draw the line 
between “advanced” rope climbing and ordinary rope 
climbing; between powerboat racing and super bike 
racing; or between scuba diving at depths greater or 
lesser than 40 meters? These distinctions appear to be 
arbitrary, and as a result, unfair and unjust. In fairness, 
the risk in scuba diving is more closely linked to one’s 
training and experience than merely the depth that one 
dives at. Other seemingly hazardous activities, such as 
rugby union, rugby league, micro-lighting, skydiving, 
boxing, wrestling and martial arts are conspicuously 
excluded from the above list, yet arguably carry a greater 
risk of injury to life and limb than those expressly cited. It 
is submitted that clear and concise empirical research by 
a scheme-independent body be included so that the 
public can understand the justification for such specified 
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exclusions.  What scheme membersrequire in this regard, 
in many of the unexplained exceptions, is an expectation 
of being treated fairly and reasonably.  
 
3.3.8 Contraceptives: 
 
This exclusion appears strange for several reasons. The 
first is the direct comparative cost to the scheme of 
paying for contraceptive devices / treatments on the one 
hand as opposed to paying towards the cost of 
gynaecological visits, child birth and all medical expense 
of the child for the first 18 years of its life on the other 
hand. 
 
Furthermore, low-dose triphasic oral contraceptives have 
been shown to be an effective medical treatment for skin 
conditions such as acne vulgaris (Lemay et al., 1990: 8 - 
14) as have so-called combined oral contraceptives 
(Koltunet al., 2008: 249).   
 
An argument that could be raisedby a scheme as 
justification for not paying for contraceptives is that it 
encourages sexual activity and / or promiscuity. This, 
however, must be countered with the post-modern reality 
that children / young adults are becoming sexually active 
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at a progressively younger age in any event (Kaestleet al, 
2005: 777), and the potential payment for contraceptives 
by medical aids would not have a material bearing on the 
level of promiscuity in society. Indeed, there may be a 
greater risk to society in an increase in unplanned 
pregnancies, unwanted children and the linked socio-
economic costs that are inextricably linked thereto. 
 
3.3.9Smoking cessation and anti-smoking 
preparations: 
 
The financial burden on the health infrastructure that is 
attributable to smokers is significant on account that 
tobacco is estimated to be the largest single cause of 
premature deaths in developed countries (Peto et al., 
1992: 1268). To be more specific, smokers are more 
likely to develop emphysema (Auerbachet al., 1972: 853), 
oesophageal cancer (Funkhouser& Sharp, 1995: 1119), 
lung cancer (Cornfield et al., 2009: 1175) and pneumonia 
(Almirall et al., 1999: 375), amongst respiratory and other 
diseases, than are non-smokers. 
 
Recent developments in the South African Tobacco / 
Anti-smoking legislation have begun the process of 
curbing the very destructive habit of smoking, but this is 
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not enough. Smoking, and specifically the nicotine 
contained in cigarettes, is addictive (Dani& De Biasi, 
2001: 439). In the interest of the health of their members, 
it is submitted that medical aids are ethically bound, from 
both a beneficent and a just perspective, to provide 
payment for proven methods of assisting in the process 
of smoking cessation. Not only will society (specifically 
the general health and wellbeing thereof) as a whole 
benefit, but the direct cost of anti-smoking treatments is 
but a fraction of the cost of treating smoking related 
conditions such as those cited above.It is consequently 
submitted that medical aid companies should be ethically 
bound, and financially responsible to pay for anti-smoking 
treatments. 
 
 
3.3.10Organ Donation: 
 
The majority of organs for transplantation come from 
cadavers, but as these have failed to meet the growing 
need for organs, attention has turned to organs from 
living donors (Truog,2005: 444). Organ donation by living 
donors presents a unique ethical dilemma, in that 
physicians must risk the life of a healthy person to save 
or improve the life of a patient. Transplantation surgeons 
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have therefore been cautious in tapping this source (Ibid). 
However, as surgical techniques and outcomes have 
improved, this practice has slowly expanded. 
 
Fedhealth excludes payment for organ donation unless 
therecipient is a member / dependant of a member of 
their scheme. There is no indication as to why the costs 
of the donor should not be covered if the recipient were 
on another medical scheme, or not a member of a 
scheme at all. 
 
In the alternative, it would be unreasonable to expect a 
donor to pay for all of the costs associated with a 
donation of an organ (or part thereof), particularly if 
performed entirely for beneficent reasons. If the would-be 
recipient is a member of a medical aid, it is submitted that 
such medical scheme has an obligation to pay for life-
saving surgery, which in this case is organ donation. The 
costs of such procedure would not only include the costs 
of the recipient, but also those of the donor, without 
whom such life-saving surgery would not be possible. For 
a medical scheme to exclude payments for organ 
donation, it would necessarily be disregarding all four bio-
ethical pillars, namely, respect for patient autonomy, 
justice, beneficence and non-maleficence. 
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To be more specific, if both recipient and donor, in 
knowing the associated risks, autonomously elect to 
undergo surgical transfer of tissue from donor to 
recipient, and there is a scientific likelihood of success, 
then it would not be fair or just to deprive the recipient of 
the opportunity of lifesaving treatment on account of the 
cost. Remember, the primary function of medical 
insurance is to fund the expenses associated with 
unforeseen medical procedures and treatments, and the 
need for organ donation would invariably not have been 
contemplated in advance by the would-be recipient, 
making the treatment unforeseen and lifesaving. It is 
hence difficult to understand how payment for organ 
donation could be excluded for any other reason besides 
being an arbitrary mechanism of limiting member 
benefits. 
 
Furthermore, it is submitted that from an economic 
perspective, the cost of a kidney transplant for example is 
substantially lower than that of on-going, long-term 
dialysis, which the scheme would otherwise pay for. 
Medical schemes could, in the circumstances, generate 
significant goodwill by becoming innovative and including 
procedures such as organ donation on their list of 
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approved treatments / procedures, and in so doing, 
illustrate to the public how such scheme has incorporated 
bioethics into adynamic funding protocol for the benefit of 
the member (as well as the fiscal benefit of the scheme). 
 
3.3.11Haemopoeitic stem cell (bone marrow) 
donations: 
There should be no difference in principle between 
payment structures for bone marrow donation and 
‘ordinary’ organ donation, as above. 
 
3.4Innovative Express / Implicit Provisions in respect 
of the above Exclusions: 
 
3.4.1 Failure to follow the advice of medical 
practitioners: 
 
If a member experiences certain complications or a 
worsening of their underlying condition on account of 
failing to heedthe advice of their medical practitioner, then 
there exists no justification for the relevant medical 
scheme to be compelled to pay for any subsequent 
treatment brought about by such failure. Such failure 
could in fact be seen as being tantamount to wilfully 
(voluntarily) inflicted injury or harm on one’s self, and if 
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such conduct was wilful, regardless of the subjective 
reasoning involved, the member should on all accounts 
be responsible for the costs of remedying any damage 
caused thereby. 
 
3.4.2 Medicines prescribed by a person not legally 
entitled to do so: 
 
Only qualified medical doctors who are registered with 
the Health Professions Council of South Africa are 
authorised to formally prescribe medications. This is so in 
order to ensure that if the medication was incorrectly 
prescribed, there exists a right of recourse against the 
doctor with his / her professional regulatory body and / or 
litigiously in Court, whether in terms of a civil suit or a 
criminal charge (dependant on the circumstances. 
 
Members must know that by purchasing medication 
prescribed by someone not authorised to do so, they are 
risking their lives and health voluntarily, and hence 
exposing themselves to significant medical costs for 
which the medical schemes should not have to bear any 
responsibility. This provision is clear, concise and 
specifically intended to protect the members’ interests, 
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and it is submitted that such provision should be cited in 
every medical aid contract. 
 
3.4.3 Anabolic Steroids: 
 
Steroids are prescribed for differing reasons. There are 
two broad categories of steroids, namely cortico-steroids, 
being any steroid hormone synthesized by the adrenal 
cortex (Martin, 2007: 168), and anabolic steroids, being 
synthetic forms of male sex hormones (Martin 2007: 28). 
 
Cortico-steroids (such as budesonide) assist in broncho-
dilation (Barnes et al., 1998: S1),whilst anabolic steroids 
such as deca-durabolin have been used to provide anti-
inflammatory relief to injured joints and muscles due in 
part to increased haemoglobin levels (Kotler, 2000: 629), 
Testosterone Cypionate to intentionally stunt one’s 
growth in the treatment of Gigantism and metastatic 
breast cancer (Lupulescu, 1998: 2265) 
(Eugster&Pescovitz, 1999: 4382)and various testosterone 
derivatives such as prednisone are being used effectively 
as part of the treatment regimen of certain types of 
cancer (Tannock et al., 1996: 1756; Tannock et al.,1989: 
590).From the above, an argument could be madethat 
 - 62 -
anabolic steroids properly prescribed for such legitimate 
purposes should be paid for out of scheme benefits. 
 
However, it seems that the largest demographic in terms 
of anabolic steroid use is in respect of illegal performance 
enhancement in sport and / or for leisure and recreational 
use (Parkinson & Evans, 2006: 644-651). Steroid use, 
and particularly at levels greater than relevant therapeutic 
doses, is linked to severe side-effects such as liver 
damage (See et al.,1992: 73), kidney damage (Daher et 
al.,2009: 717), gynecomastia (Babigian& Silverman, 
2001: 240), impotence (Bickelman et al., 1995: 158), 
heart attacks (Welder &Melchert,1992: 61) and certain 
types of cancers (Nieminen et al., 1996: 1580).  
 
For these reasons, in addition to the fact that the use of 
such drugs would invariably not be in line with a 
recognised therapeutic protocol, the medical schemes 
are justified in excluding payment for anabolic steroids. It 
must however be reiterated that bona fide and legitimate 
use of steroids for medical purposes should be 
considered for payment by the relevant scheme. 
 
 
3.5Money-Saving Mechanisms for Medical Schemes: 
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3.5.1 Original versus Generic Drugs: 
An original “patented” drug is regarded as a pioneer in its 
niche category, having been subjected to thousands of 
hours of research and development. As such, patented 
drugs are available at a premium in order to offset such 
costs. Generic drugs are those utilising the same active 
ingredients as the patented drugs, and are generally 
made available once the patent on the original drug 
expires (Bae, 1997: 87). Medical Aid companies 
frequently pay only for the cost of the generic drug 
because the patented drug is viewed as an unnecessary 
expense. 
 
“For the purposes of drug approval, the interchangeability 
of a generic drug and the corresponding brand-name 
drug is based on the criterion of “essential similarity”, 
which requires that the generic drug have the same 
amount and type of active principle, the same route of 
administration, and the same therapeutic effectiveness as 
the original drug, as demonstrated by a bioequivalence 
study.” 
(Borgheini, 2003: 1578)  
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Difficulties materialise, however, when the efficacy of the 
generic drug is not congruent with that of the patented 
drug, or alternatively were the generic drugs causes 
certain adverse reactions that the patented drugs do not. 
Published findings indicate that particular drugs may not 
be ideally suited for generic substitution when a patient 
has already been taking that drug (Tschabitscher et al., 
2008: 63). A member would thus not be physically able to 
continue on the generic drug and would of necessity be 
forced to use the patented drug. Yet the scheme would 
invariably only pay the equivalent of the price of the 
generic drug, with the difference in price often being 
rather significant. In such circumstances, it is only fair and 
just for the medical aids to re-instate their coverage of the 
patented drug in the interests of fairness and non-
maleficence to their members.  
 
Doctors frequently stipulate on patients’ scripts the words 
“do not substitute” or the like, having their own medical 
reasons for doing so. A particular individual patient may 
react adversely to a generic and not so in respect of the 
patented drug. Although this theoretically should not 
happen, in reality it does. In this regard, and in the 
absence of suspicious conduct by the prescribing doctor 
 - 65 -
(possibly in relation to receiving kickbacks from drug 
companies), the medical schemes are obliged to abide by 
the doctor’s instruction to “not substitute”. 
 
For the sake of completeness, it must be stated that 
Section 47 of the Medical Schemes Act, Act 131 of 1998, 
provides for a grievance procedure in this regard, in that: 
 (1) The Registrar shall, where a written complaint 
in relation to any matter provided for in this Act 
has been lodged with the Council (being the 
Council for Medical Schemes), furnish the party 
complained against with full particulars of the 
complaint and request such party to furnish the 
Registrar with his or her written comments 
thereon within 30 days or such further period as 
the Registrar may allow.  
(2)  The Registrar shall, as soon as possible after 
receipt of any comments furnished to him or her 
as contemplated above, either resolve the matter 
or submit the complaint together with such 
comments, if any, to the Council, and the Council 
shall thereupon take all such steps as it may 
deem necessary to resolve the complaint.  
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One can easily see though that this process is both 
inherently bureaucratic and time consuming, and hence 
does not necessarily deal with the cause of complaint 
within the realms of medical / financial urgency as 
experienced by the member. 
 
 
Members should thus be both entitled and encouraged, in 
circumstances of their claims for patented drugs being 
repudiated by their medical scheme in favour of the 
generic equivalent, to request to see the clinical research 
/ bioequivalence study proving that the generic is just as 
effective and has no greater side-effects than the 
patented drugs. In the absence of such research, it is 
submitted that the medical scheme should not refuse to 
pay for the patented drug. Furthermore, as there is an 
international expansion of the counterfeit generic drug 
trade particularly in developing countries, it would be 
prudent to be flexible in the position that medical 
schemes take concerning generic drugs (McNeil, 2000: 1-
5; Foster, 1991:1213-1214).  
 
 
3.5.2 Payment of Service Providers at Medical Aid 
Tariff: 
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The Doctor-patient relationship is quite unique. It contains 
elements of not only general law of contract, where the 
patient pays for services rendered, but also a fiduciary 
duty of the doctor. This duty requires that the onus isupon 
the doctor to treat the patient as comprehensively as may 
be necessary, to spend sufficient time with the patient 
during a consultation in order to ascertain the cause of 
the complaint and its consequent remedy, and to hold 
paramount the best interests of the patient above all other 
considerations (Health Professions Council of South 
Africa (ii) 2008). 
 
Indeed, as Hall (2008) reminds us: The most conspicuous 
aspect in which the law alters the normal contractual 
status of medical care is to declare in a variety of 
contexts that physicians owe fiduciary-like duties to their 
patients. Multiple cases say something to the effect that 
there is more between a patient and his physician than a 
mere contract under which the physician promises to heal 
and the patient promises to pay.  
 
There is an implied promise, arising when the physician 
begins treating the patient that the physician will refrain 
from engaging in conduct that is inconsistent with the 
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“good faith” required of a fiduciary. The patient should, we 
believe, be able to trust that the physician will act in the 
best interests of the patient thereby protecting the 
sanctity of the physician-patient relationship (Hall, 2008). 
 
Particularly in emergency situations and / or where the 
expertise of a specific clinician are sought, the quasi-
fiduciary nature of the physician’s role, the vulnerability 
and possible incompetence of the patient, the exigency 
that often surrounds illness, and the tremendous 
complexity of modern medicine all serve to impair the 
prospects for effective bargaining over the scope and 
nature of treatment rendered by the physician (Siliciano, 
1991). The patient consequently requires the certainty 
that their medical scheme will cover the cost of the 
attending doctor in the absence of time for such patient to 
shop around and locate the most cost effective clinician. 
 
However, if medical aid schemes set a tariff in terms of 
which a clinician will be paid at a rate which does not 
bear a realistic nexus to a market related cost, taking into 
account the said clinician’s academic qualifications, 
experience, overheads and the need to make a profit on 
his charge-out rate, then the clinician is being pushed to 
spend the minimum time necessary with the patient in 
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order to have capacity to consult with more patients per 
day. This economic coercion has a substantial and 
detrimental effect on the level of care shown to the 
patient. 
 
It is a given that a good doctor should know how to 
manage time. When a patient’s symptoms are 
straightforward it can be argued that a doctor can  
accurately define and explainto a patient in a clear and  
accessible language the problem, a discussion 
concerning  proposals for treatment, and patient reflection  
within a twenty minute visit. However, not all complaints 
are straight-forward and complicated problems cannot be 
solved so quickly.  
 
As Groopman (2008: 88) writes:  
A discerning doctor will recognise when more time is 
needed to ask questions and explain his thinking. In such 
instances, the appointment may need to be extended or a 
follow-up visit scheduled as soon as feasible. Cogent 
thinking and clear communication cannot be conducted 
like a race being run. Despite all the pressures to limit 
time in managed care and the pursuit of putative 
efficiency, doctors and patients should push back. 
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Finding the right answer often takes time. Haste makes 
cognitive errors. 
 
Many doctors have consequently stopped charging 
medical aid tariffs, and do not consider themselves bound 
thereby. If a doctor were to submit his invoice to the 
patient’s medical aid scheme for payment, he or she 
would not be paid directly, but the tariff amount would 
rather be paid into the patient (scheme member’s) bank 
account. This then creates logistical and legal problems 
for the doctor in trying to recover the money from a 
(dishonest) patient who may not have the need consult 
the doctor again. Because of this, the patient may feel 
less obligated to tender payment for services rendered. 
This being said, the doctor also realizes that it would 
make no sense to litigate against such patients for 
relatively paltry amounts of money because the legal fees 
involved will significantly outweigh the debt. 
 
Whereas the initial idea of medical aid societies was that 
they would enable their members to afford private 
medical care, after the advent of the Medical Schemes 
Act, which gave statutory recognition to the 
Representative Association of Medical Schemes, the 
medical aid movement, in the guise of protecting the 
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public, took it upon itself to interfere with both the 
contents as well as the level of tariffs, with what I have 
always believed to be a spurious claim, viz. that they 
were acting in the best interests of the patients!  
(Le Roux, 2004) 
 
Clinicians have consequently started to demand payment 
from the patient up front or, at the very least, upon 
conclusion of the consultation. The patient will then pay 
the clinician the full charge-out rate, submit a claim to 
their medical scheme, and will subsequently be 
reimbursed by the scheme, but only up to the scheme 
approved tariff amount. Indeed, as far afield as the United 
States of America, some physicians are converting to 
cash-only practices that refuse all forms of insurance 
(Hall, 2008). 
 
3.5.3 Capping of annual escalations of Medical Aid 
Tariffs below CPI: 
 
Studies conducted by an independent health care 
consultancy, HealthMan6, indicate that the current 
National Health Reference Price List tariffs will have to 
                                                 
6
 Health Man is a privately owned healthcare consultancy for the 
management and administration of specialist and healthcare 
networks. 
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increase by at least 170% for procedures and by 120% 
for specialist consulting codes to reflect the cost of 
running a private practice. For General Practitioners, a 
further increase of at least 25% will be required 
(Bateman, 2009). The results of these studies (of 1 296 
specialist and GP practices) were presented to the 
Department of Health on 20 May 2008 and were 
‘consistent’ with the South African Medical Association’s 
submissions exactly a year earlier (ibid).  
 
If we were to analyse the cost of consulting with private 
practitioners, most doctors need their own (expensive) 
equipment. We do not live in a society which dictates that 
independent practitioners (regardless of industry) need to 
pool their resources in order to curb collective costs. 
Partnerships, whether medical or in any other commercial 
environment, are fraught with financial pitfalls for those 
concerned, and a practitioner should be free to choose 
how he / she structures his / her practice. If this is indeed 
done on a solitary basis, then the need for one’s own 
equipment is self-explanatory. Alternatively, many 
practices choose to lease their equipment for a set 
monthly cost. Such cost is generally very high, but the 
leases are generally designed to include any unforeseen 
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maintenance costs as well as replacement costs when 
newer / better equipment is launched. 
 
 
It is submitted that it borders on false and misleading 
marketing practices for medical aidschemes  to advertise 
that their particular scheme pays up to 300% of tariff for 
instance, where the actual cost of a procedure or 
consultation may in fact be 400 – 500% of the said tariff. 
In the patient’s mind, he or she believes that if their 
scheme pays up to 300% of the tariff that there should 
logically be no shortfall, however such member does not 
realize how low the tariffs actually are actually structured. 
Medical aid tariffs should hence bear some semblance to 
the realistic charges thatneed to be levied by practitioners 
in order to generate a profit. This is simply a requirement 
of justice and equity. 
 
In this chapter, I have illustrated at least the principal 
contentious issues that currently befall the relationship 
between medical scheme and member. In the following 
Chapter, I shall discuss the extent to which the Consumer 
Protection Act is likely to have a bearing on this 
relationship. 
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Chapter 4:The Consumer Protection Act 
 
4.1 Introduction 
 
The Consumer Protection Act became fully operational 
on 1 April 2011. The Act lays the foundation for an era of 
the consumer in South Africa by introducing a single, 
comprehensive legal framework for consumer protection. 
Notable features include the introduction of necessary 
consumer rights, a Consumer Court, a Consumer 
Commission to serve as an investigative body for 
consumer complaints, and a Consumer Tribunal to 
adjudicate upon alleged serious breaches of the Act by 
suppliers and service providers. 
 
4.2 Purpose and policy of the Act 
The purpose of the Consumer Protection Act is to provide 
a framework for greater consumer protection. Therefore, 
should it be found that the Consumer Protection Act 
offers a greater degree of consumer protection than any 
conflicting legislation (which will invariably be the case), 
including the Medical Schemes Act, then the relevant 
provisions of the Consumer Protection Act shall, in terms 
of sections 2 (8) – (10), take precedence. 
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 The following serves as a brief exposé regarding how the 
Act impacts on the ethical and legal relationship between 
medical schemes and members. 
 
The specific provisions relevant to the legal and ethical 
relationship between a medical scheme and its members 
are set out below: 
 
3. (1) The purposes of this Act are to promote and 
advance the social and economic welfare of 
consumers in South Africa by— 
… 
(b) reducing and ameliorating any disadvantages 
experienced in accessing any supply of goods or 
services by consumers— 
… 
 (iv) whose ability to read and comprehend 
any advertisement, agreement, mark, 
instruction, label, warning, notice or 
other visual representation is limited 
by reason of low literacy, vision 
impairment or limited fluency in the 
language in which the representation 
is produced, published or presented; 
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(c) promoting fair business practices; 
 
(d) protecting consumers from— 
(i) unconscionable, unfair, unreasonable, 
unjust or otherwise improper trade 
practices; and 
(ii) deceptive, misleading, unfair or 
fraudulent conduct; 
(e) improving consumer awareness and 
information and encouraging responsible and 
informed consumer choice and behaviour; 
 
(g) providing for a consistent, accessible and 
efficient system of consensual resolution of 
disputes arising from consumer transactions;  
 
In this regard, when interpreting the Consumer Protection 
Act, one must take into account the legally recognised 
mechanisms for doing so: 
“If a provision has two possible meanings, thecontra 
fiscum rule applies (Estate Reynolds v CIR, 1937 
AD 70). This means that the meaning that benefits 
theindividual is accepted (SIR v Raubenheimer, 
1969 4 SA 314 (A)). As Van Niekerk (1971: 145) 
rightly points out, “this is actually an application of 
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the rule semper in dubiisbenigniorapraeferendasunt 
(in cases of doubt, the most beneficial interpretation 
should be adopted). Generally speaking, this 
principle is fully in accordance with the spirit and 
scope of the fundamental rights entrenched in the 
Bill of Rights.”(Botha, 1998: 70) 
 
Accordingly, wherever possible, the Consumer Protection 
Act should be interpreted to the benefit or advantage of 
the consumer, or in this specific case, the medical aid 
member. This represents a modern example of a 
preference, in the case of interpretative ambiguity, for the 
collective good to prosper over a single (commercial) 
entity. 
 
4.3 The Consumer’s Right to Choose 
The Act re-enforces the Consumer’s right to freedom of 
choice, which right is also to be found in section 18 of the 
Constitution (Constitution of the Republic of South Africa, 
Act 108 of 1996). In the context of a member of a medical 
scheme, such member should not be prevented from 
consulting with medical professionals of his or her choice.  
 
Prevention, in this sense, takes into account that if a 
scheme refuses to pay for or towards the costs of such 
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consultation, they are, in effect, preventing the member 
from consulting the practitioner concerned. In this regard, 
section 13 of the Act stipulates: 
 
13. (1) A supplier must not require, as a condition 
of offering to supply or supplying any goods or 
services, or as a condition of entering into an 
agreement or transaction, that the consumer 
must— 
 (b) enter into an additional agreement or 
transaction with the same supplier or a designated 
third party; or 
(c) agree to purchase any particular goods or 
services from a designated third party, unless the 
supplier— 
(i) can show that the convenience to the 
consumer in having those goods or 
services bundled outweighs the 
limitation of the consumer’s right to 
choice; 
(ii) can show that the bundling of those 
goods or services results in economic 
benefit for consumers; or 
(iii) offers bundled goods or services 
separately and at individual prices. 
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… 
Frequently, Medical Aid companies offer schemes to the 
lower-income population bracket, in terms of which 
scheme members’ medical consultations shall be paid for 
directly by the scheme on the express condition that the 
member consults with only those clinicians on a pre-
selected list of preferred service providers as provided by 
the scheme. It would appear that such a scheme 
contravenes Section 13(1) on account that such practices 
cannot be justified by “the convenience to the consumer 
in having those … services bundled outweighing the 
limitation of the consumer’s right to choice, or the 
bundling of those … services resulting in economic 
benefit for consumers” (section 13(1)(c)(iii) does not 
apply). 
 
This type of scheme removes a significant portion of the 
patient’s autonomy from the spectrum of patient rights in 
exchange for an arrangement in terms whereof the 
selected doctors charge the medical aid lower rates in 
exchange for more pairs of feet being herded through 
their doors. It could be submitted in this regard that 
autonomy can only be removed from a patient, especially 
a patient who for any reason cannot understand the 
significance and purport of such removal, in 
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circumstances of emergency, and then only to the extent 
that such emergency dictates.  
 
It could be argued that this practice is furthermore 
“unconscionable”, in terms of the Act, on two bases, 
namely: 
i) The quality of medical practitioners differ according 
to experience and expertise. To deny a member 
the opportunity to consult with a clinician of 
sufficient skill, as may be required in a given 
circumstance seems entirely “unfair and unjust”; 
and 
 
ii) Particularly in a medical context, severe prejudice 
could be suffered by a member who may have to 
travel significant distances to consult with a 
scheme-approved clinician when a more 
expensive yet unapproved clinician may be 
geographically more convenient  
 
 
 
4.4 The right to information in plain and 
understandable language 
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The phraseology of medical aid contracts contains 
numerous references to technical jargon and complicated 
language, rendering the contract difficult for the average 
reasonable person to sufficiently comprehend. In this 
regard, section 22 states: 
 
22. (1) The producer of a notice, document or 
visual representation that is required, in terms of 
this Act or any other law, to be produced, provided 
or displayed to a consumer must produce, provide 
or display that notice, document or visual 
representation— 
 
(b) in plain language, if no form has been 
prescribed for that notice, document 
orvisual representation. 
(2) For the purposes of this Act, a notice, 
document or visual representation is in 
plain language if it is reasonable to 
conclude that an ordinary consumer of the 
class of persons for whom the notice, 
document or visual representation is 
intended, with average literacy skills and 
minimal experience as a consumer of the 
relevant … services, could be expected to 
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understand the content, significance and 
import of the notice, document or visual 
representation without undue effort, having 
regard to— 
(a) the context, comprehensiveness and 
consistency of the notice, document orvisual 
representation; 
(b) the organisation, form and style of the notice, 
document or visual representation; and 
(c) the vocabulary, usage and sentence structure 
of the notice, document or visualrepresentation;  
 
Having perused and considered the list of exclusions of 
the aforesaid five medical schemes, a solid argument can 
be made that such exclusions, and indeed the greater 
medical insurance contract as a whole, are frequently 
drafted in a manner that is not in plain language. The 
ordinary consumer / prospective member with average 
literacy skills and minimal experience as a consumer of 
the relevant services, cannot reasonably be expected to 
understand the content, significance and import of the 
documents in question.  
 
In this regard, note should be taken of the organisation of 
the contents of the aforesaid documents, as well as the 
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vocabulary used therein. There appears to be too much 
in the way of either legal or medical jargon for the 
average member to comprehend.  
 
Considering that most medical aid members contract with 
their various schemes through a broker / intermediary, 
such broker / intermediary should be in a position to 
answer all questions from the prospective member in 
respect of terminology that is not clearly understood. This 
means that the broker / intermediary will be making 
representations on behalf of the scheme to prospective 
members. These representations will vary in import and 
significance, and in respect of which the medical aid 
scheme / company or the subsidiary scheme has no 
control.  
 
This represents a significant risk to the medical aid / 
scheme because the Consumer Tribunal, in taking into 
account the spirit and purport of the Act, will be likely to 
rule in favour of a complainant who contracted with such 
medical aid / scheme on the basis of, and in terms of 
certain representations made by their authorised agent or 
representative, which in this case, is the broker or 
intermediary. 
 
 - 84 -
In order to minimise this risk, it is advisable for medical 
aids to appoint several persons to the role of “Contract 
Interpretation Advisor”,whom prospective members can 
contact in advance of signing their medical aid contracts 
in order to clarify any areas of concern or confusion that 
may have arisen either by a diligent perusal of the 
documentation, or as a result of the consultation between 
the broker and the prospective member.  
 
Reference to this “Contract Interpretation Advisor” would 
appear in the contractual documents, and should in 
addition be pointed out to the prospective member by the 
broker. In this way, the medical aid / scheme has acted 
pro-actively in attempting to prevent misunderstandings 
and misrepresentations, resulting in the prospective 
member making a more informed decision in respect of 
whether to subscribe to a particular medical scheme or 
not. 
 
Brokers, are by their very nature, independent agents 
with their own priorities and agendas, but the proposed 
Contract Interpretation Advisor would work for the 
medical scheme and hence have a fiduciary duty to act in 
good faith, cognisant of the legal and ethical implications 
of his advice. 
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Finally, it would appear that the appointment of a 
“Contractual Interpretation Officer” would make the 
facilitation and implementation of the Consumer 
Protection Act more manageable for the medical aid 
companies, vesting themselves with greater control. As 
such, compliance with the Act would then be that much 
easier. 
 
4.5 Disclosure of price of goods or services 
 
Section 23 of the Act stipulates:  
 
(3) … a retailer must not display any goods for 
sale withoutdisplaying to the consumer a price in 
relation to those goods. 
(6) a supplier must not require a consumer to pay 
a price for any goods or services— 
(a) higher than the displayed price for those 
goods or services; 
 
What is significant about section 23 in respect of the 
Medical aid schemes /industry is that a price (of monthly 
contributions towards a medical scheme) should always 
be clearly displayed, including on the internet website of 
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the scheme, and that if, per chance, two different pricing 
references to the same scheme are made, that 
prospective clients would only be charged the lesser of 
the said two prices. 
 
4.6 Unconscionable conduct 
 
Section 40 of the Act states that:  
 
(2) … it is unconscionable for a supplier knowingly 
to take advantage of the fact that a consumer was 
substantially unable to protect their own interests 
because of … ignorance, inability to understand 
the language of an agreement, or any other 
similar factor. 
 
It is submitted that section 40(2) provides added impetus 
and necessity for medical schemes to appoint “Contract 
Interpretation Advisors” as described above. Prospective 
and existing members should have the right to contact a 
suitably qualified scheme employee to timeously advise 
them of the correct contractual interpretation ascribed to 
certain problematic or complicated provisions. In this 
manner, the scheme could not be said to have taken 
advantage of any prospective or existing member on 
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account of such person’s ignorance, inability to 
understand the language of an agreement, or any other 
similar factor on account that facilities were proactively 
made available to the member for the express purpose of 
clarifying any confusion / ambiguity. 
 
4.7 The right to fair, just and reasonable terms and 
conditions 
 
Section 48 stipulates that: 
 
48. (1) A supplier must not— 
(a) offer to supply, supply, or enter into an 
agreement to supply, any goods or 
services— 
(i) at a price that is unfair, unreasonable or 
unjust; or 
(ii) on terms that are unfair, unreasonable 
or unjust; 
(b) market any goods or services, or 
negotiate, enter into or administer a 
transaction or an agreement for the 
supply of any goods or services, in a 
manner that is unfair, unreasonable or 
unjust; or 
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(c) require a consumer, or other person to 
whom any goods or services are 
supplied at the direction of the 
consumer— 
(i) to waive any rights; 
(ii) assume any obligation; or 
(iii) waive any liability of the supplier, 
on terms that are unfair, unreasonable or 
unjust, or impose any such terms as a 
condition of entering into a transaction. 
 
It remains to be seen, in relation to section 48(1), which 
person or entity shall be responsible for determining what 
conduct falls under the ambit of “unfair, unreasonable or 
unjust”. It is submitted that where a medical scheme 
excludes too many conditions or procedures, or 
alternatively excludes a broad category / genre of 
conditions or procedures with no exception made for 
grounds of justification, that such exclusions shall be held 
to be unfair, unreasonable and / or unjust. An example of 
the above is Discovery Health, Spectramed and Oxygen’s 
general exclusion of all cosmetic procedures. In this 
regard, there appears to be a clear focus on elective 
cosmetic procedures being excluded, however, where 
there is medical justification for the procedure in question, 
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it is submitted that to continue to exclude such a 
procedure would be profoundly unfair. 
 
An example of medical justification could be where a 
psychiatrist has drafted a formal opinion stating that the 
patient / member presently suffers / is likely to suffer from 
clinical depression (and the associated sequelae thereof) 
as a result of having a double mastectomy which was in 
itself necessary on account of breast cancer. To deny the 
member the facility of paying for a breast reconstruction 
seems iniquitous and against public policy. Furthermore, 
in the absence of a breast reconstruction procedure, the 
scheme would of necessity have to pay for anti-
depressant and other medication for an extended 
duration, which cost will, in the medium to long term, in 
fact amount to more than the cost of the breast 
reconstruction surgery. 
 
Section 48(2) stipulates: 
 
(2) Without limiting the generality of subsection 
(1), a transaction or agreement, a term or 
condition of a transaction or agreement, or a 
notice to which a term or condition is purportedly 
subject, is unfair, unreasonable or unjust if— 
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 (a) it is excessively one-sided in favour of 
any person other than the consumer or 
other person to whom goods or 
services are to be supplied; 
(b) the terms of the transaction or 
agreement are so adverse to the 
consumer as to be inequitable; 
(c) the consumer relied upon a false, 
misleading or deceptive representation, 
as contemplated in section 41 or a 
statement of opinion provided by or on 
behalf of the supplier, to the detriment 
of the consumer;  
 
It remains to be seen, in relation to section 48(2), which 
person or entity shall be responsible for determining what 
conduct falls under the ambit of excessively one-sided, 
although it is submitted that where a person is a member 
of a particular scheme that is intended to be 
comprehensive in nature, a list of exclusions that is too 
onerous, or specific exclusions which bear no logical 
nexus to the fair, just and reasonable intention of the 
policy / scheme, will be deemed excessively one-sided. 
 
4.8 Notice required for certain terms and conditions 
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Frequently, terms of medical aid contracts are drafted in a 
manner that is very onerous for the consumer (member). 
To this extent, section 49 stipulates that: 
 
49. (1) Any notice to consumers or provision of a 
consumer agreement that purports to— 
(a) limit in any way the risk or liability of the 
supplier or any other person; 
(b) constitute an assumption of risk or 
liability by the consumer; 
(c) impose an obligation on the consumer 
to indemnify the supplier or any other 
person for any cause; or 
(d) be an acknowledgement of any fact by 
the consumer, must be drawn to the 
attention of the consumer in a manner 
and form that satisfies the formal 
requirements of subsections (3) to (5). 
 
The relevant lists of exclusions spell out the 
circumstances in which the scheme’s liability is limited 
and where the member assumes a certain degree of 
financial risk. It can be argued that by doing so, the 
medical aids are drawing adequate attention to the 
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exclusions in plain language, and that they give the 
consumer / prospective member an adequate 
opportunity in the circumstances to receive and 
comprehend the provision or notice. However, although 
one can debate whether the language utilised in such 
lists of exclusions is indeed “plain”, it is doubtful that a 
scheme could reasonably believe that all of its members, 
at the time of subscribing to their policies, had a 
sufficient opportunity to examine and comprehend the 
length and breadth of the said exclusions.  
 
It is submitted that there exists some scope in this regard 
to strengthen the wording of the contracts to include a 
provision stating: “The member has had sight of the list 
of exclusions in respect of which the scheme shall make 
a limited / no financial contribution. The member 
understands the import and consequences of such 
exclusions, which are hereby incorporated into and form 
part of this medical aid contract.”  
 
The corollary of this is that the member has a 
responsibility to ask all relevant questions of the broker 
as to the import and consequences of the exclusions. 
This statement is premised on the assumption that the 
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author’s suggestion of medical aid companies employing 
“Contract Interpretation Advisors” is not taken up. 
 
(2) In addition to subsection (1), if a provision or notice 
concerns any activity or facility that is subject to any 
risk— 
(a) of an unusual character or nature; 
(b) the presence of which the consumer 
could not reasonably be expected to be 
aware or notice, or which an ordinarily 
alert consumer could not reasonably be 
expected to notice or contemplate in 
the circumstances; or 
(c) that could result in serious injury or 
death, the supplier must specifically 
draw the fact, nature and potential 
effect of that risk to the attention of the 
consumer in a manner and form that 
satisfies the requirements of 
subsections (3) to (5), and the 
consumer must have assented to that 
provision or notice by signing or 
initialling the provision or otherwise 
acting in a manner consistent with 
acknowledgement of the notice, 
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awareness of the risk and acceptance 
of the provision. 
 
(3) A provision, condition or notice contemplated 
in subsection (1) or (2) must be written in plain 
language, as described in section 22. 
 
(4) The fact, nature and effect of the provision or 
notice contemplated in subsection (1) must be 
drawn to the attention of the consumer— 
(a) in a conspicuous manner and form that 
is likely to attract the attention of an 
ordinarily alert consumer, having 
regard to the circumstances; and (b) 
before the earlier of the time at which 
the consumer— 
(i) enters into the transaction or agreement, 
begins to engage in the activity, or 
enters or gains access to the facility; or 
(ii) is required or expected to offer 
consideration for the transaction or 
agreement. 
(5) The consumer must be given an 
adequate opportunity in the 
circumstances to receive and 
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comprehend the provision or notice as 
contemplated in subsection (1). 
 
A contractual exclusion could be seen as being of 
an unusual character or nature; or that the 
consumer could not reasonably be expected to be 
aware of or have contemplated such provision; or 
that could result in serious injury or death, where 
for instance, Spectramed and Fedhealth stipulate 
that any benefit not specifically stated in the 
scheme rules is excluded, which places an 
extremely onerous liability on the scheme 
member. This means that the member must know 
the specified inclusions and be able to make 
reference to them in any medical circumstance, 
due to their closed nature.  
 
One can then ask the question why, under such 
circumstances, it would be necessary to have a 
list of exclusions if everything that is not expressly 
included is excluded by default. 
 
The added stipulation that such provisions are to 
be brought to the attention of the member, 
reduced to writing and signed by the member 
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obliges the medical aids to concretise the terms 
and conditions of their policies on an annual 
basis, which terms could be updated annually if 
timeous notice to such effect is duly received by 
the member.In this regard, Dinnie opines: 
 
In the context of disclaimer and indemnity 
clauses, the provisions of section 49 create 
various formal hurdles, including specific notice, to 
the successful reliance on disclaimer(s) and 
indemnities. Except in the case of clauses that 
purport to exclude liability or indemnify in respect 
of gross negligence, there is, however, no general 
prohibition on the use of such clauses (Dinnie 
2009: 45). 
 
4.9 Written consumer agreements 
Section 50 stipulates:  
 
50. … 
(2) If a consumer agreement between a supplier and a 
consumer is in writing, whether as required by this 
Act or voluntarily— 
(a) it applies irrespective of whether or not the consumer 
signs the agreement; and 
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(b) the supplier must provide the consumer with a free 
copy, or free electronic access to a copy, of the terms 
and conditions of that agreement, which must— 
(i) satisfy the requirements of section 22; and 
(ii) set out an itemised break-down of the consumer’s 
financial obligations under such agreement. 
 
It appears that section 50(2)(a) may be diametrically 
opposed to the intention and purport of section 49(2), 
which in the context of medical aid contracts, requires 
terms which are of an unusual character or nature; or 
that the consumer may not reasonably be expected to be 
aware of or have contemplated; or that could result in 
serious injury or death, to be reduced to writing and 
signed by the member. It also seems as though this 
could be a loophole through which medical schemes can 
motivate for (excessively) onerous contracts to be 
validated, which seems contrary to the intention of the 
Act. 
 
To reiterate the purpose of the Act, Section 3(1) (d) 
specifically makes mention of protecting consumers 
from—unconscionable, unfair, unreasonable, unjust or 
otherwise improper trade practices; and deceptive, 
misleading, unfair or fraudulent conduct. Based on this, it 
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is clear that the intention of the legislature is to protect 
the consumer, and it is thus submitted that section 49(2) 
should survive a challenge emanating from the wording 
of section 50(2)(a) on the basis of the greater certainty 
and consumer protection created by section 49(2). 
 
 It is further submitted that schemes that require their 
members to pay a nominal fee in order to gain access to 
their full terms and conditions are doing so in 
contravention of section 50(2)(b). 
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Chapter 5: Concluding Remarks 
 
Commenting on the ethics related to medical insurance, 
Julian Le Grand (1991: 124-125) said that where people 
suffer ill health as a result of factors beyond their control  
 
… they should not suffer losses as a consequence. In 
cases where health risks are not obviously identifiable, 
then everyone is in some sense at equal risk and, 
therefore, everyone should bear the expected value of 
the relevant loss. 
 
In the context of the contents of this research report, it 
seems only fair to state that if someone has medical 
insurance, and suffers ill health (whether mental or 
physical) as a result of factors beyond their control, that 
such person should, as a general rule, be able to expect 
their medical insurance to cover the reasonable costs of 
any corrective treatment or procedure.  
 
It is recommended that individuals take responsibility for 
their own health, and carry medical insurance to cover 
the costs of only unforeseen medical expenses. John 
Knowles, the erstwhile president of the Rockefeller 
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Foundation, once wrote that one man’s freedom in health 
is another man’s shackles in taxes and insurance 
premiums, and urged that the idea of a “right” to health 
should be replaced by the idea of an individual moral 
obligation to preserve one’s own health (Knowles, 1977). 
In this regard, it is recommended that greater emphasis 
be placed on wellness and disease prevention, similar to 
the much publicized “Vitality” program initiated by 
Discovery. 
 
 
It is understood that medical aid companies are 
commercially profitable entities, and are run, as any 
business should be, with the intention of maximizing 
profits and minimizing expenditure. It is also 
understandable that in order to maintain the requisite 
solvency ratio of 25%, the medical aid schemes must of 
necessity implement certain exclusions and / or 
restrictions to their payment protocols in order to ensure 
the commercial viability of the business. However, this 
report has illustrated and highlighted some instances of 
exclusions that are considered as contentious issues to 
be revisited by medical schemes. In doing so, they may 
be more in line with holistic ethical medical practice and 
all applicable recent legislation. 
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Finally, it is hoped that this research report serves to 
remind both the medical aid industry and the public at 
large that there are many facets to their convoluted 
relationship, and that this relationship requires meaningful 
input, feedback and participation from both parties. 
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